Contemporary Pharmacotherapy for OAB 2021: Monotherapy and Combined Pharmacotherapy to Optimize Treatment Webcast (2021)
Much has been written and debated about drug treatment of overactive bladder (OAB) over the past two decades. Nevertheless, the field continues to evolve. OAB pharmacotherapy remains an area of active investigation, and innovation. Patient communication, including goal setting with respect to realistic expectations of therapy and therapeutic algorithms are important factors in improving patient outcomes. The publication of the recently updated AUA/SUFU Guideline entitled Diagnosis and Treatment of Overactive Bladder (Non-neurogenic) in Adults, the proceedings of the 6th International Consultation on Incontinence, as well as European Association of Urology (EAU) Guidelines has rekindled interest in this area. This course will describe the physiological and pharmacological underpinnings of modern drug treatment of overactive bladder. Currently available agents as well as drugs in development will be discussed.
Support provided by independent educational grants from AbbVie, Astellas, Medtronic, Urovant Sciences, Inc.
- Advanced Practice Providers
At the conclusion of the activity, participants will be able to:
- Define the similarities and differences between the various oral pharmacotherapies for overactive bladder (OAB).
- Review the principles of physiology and pharmacotherapy for currently available agents, including the anti-muscarinics and beta-3 agonists and combination therapy.
- Express the importance of setting proper patient expectations regarding treatment of OAB and the potential need for sequential and even additive therapies.
- Analyze the clinical (and theoretical) advantages and limitations of currently available agents.
- Discuss potential future pharmacological pathways and therapies for OAB.
METHOD OF PARTICIPATION:
Learners will participate in this online educational activity by viewing the webcast and/or listening to the podcast and completing the post-test and evaluation. To claim CME credit for this enduring material, learners must complete the post-test, passing with 80% accuracy, and submit the program evaluation.
Estimated time to complete this activity: 2.00 hours
Release Date: May, 2021
Expiration Date: March, 2022
The American Urological Association (AUA) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
The American Urological Association designates this enduring material for a maximum of 2.00 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
The AUA is not accredited to offer credit to participants who are not MDs or DOs. However, the AUA will issue documentation of participation that states that the activity was certified for AMA PRA Category 1 Credit™.
EVIDENCE BASED CONTENT:
It is the policy of the AUA to ensure that the content contained in this CME activity is valid, fair, balanced, scientifically rigorous, and free of commercial bias.
AUA DISCLOSURE POLICY:
All persons in a position to control the content of an educational activity (i.e., activity planners, presenters, authors) are required to disclose to the provider any relevant financial relationships with any commercial interest. The AUA must determine if the individual’s relationships may influence the educational content and resolve any conflicts of interest prior to the commencement of the educational activity. The intent of this disclosure is not to prevent individuals with relevant financial relationships from participating, but rather to provide learners information with which they can make their own judgments.
RESOLUTION OF IDENTIFIED CONFLICT OF INTEREST:
All disclosures will be reviewed by the AUA Conflict of Interest (COI) Review Work Group for identification of conflicts of interest. The AUA COI Review Work Group, working with the program directors and/or editors, will document the mechanism(s) for management and resolution of the conflict of interest and final approval of the activity will be documented prior to implementation. Any of the mechanisms below can/will be used to resolve conflict of interest:
- Peer review for valid, evidence-based content of all materials associated with an educational activity by the course/program director, editor, and/or AUA COI Review Work Group.
- Limit content to evidence with no recommendations
- Introduction of a debate format with an unbiased moderator (point-counterpoint)
- Inclusion of moderated panel discussion
- Publication of a parallel or rebuttal article for an article that is felt to be biased
- Limit equipment representatives to providing logistics and operation support only in procedural demonstrations
- Divestiture of the relationship by faculty
OFF-LABEL OR UNAPPROVED USE OF DRUGS OR DEVICES:
The audience is advised that this continuing medical education activity may contain reference(s) to off-label or unapproved uses of drugs or devices. Please consult the prescribing information for full disclosure of approved uses.
- 2.00 AMA PRA Category 1 Credit™
- 2.00 Non-Physician Participation